



Gary Schwartz, MD
 Co-Chair for Experimental Therapeutics and Rare Tumor Committee
 Columbia University
 177 Fort Washington Avenue, Suite 6GN-435
 New York, NY 10032
 Phone: 212-305-2055
 Email: Schwartzg@columbia.edu

Pamela N. Munster, MD
 Co-Chair for Experimental Therapeutics and Rare Tumor Committee
 University of California San Francisco
 1600 Divisadero, Rm A722 Box 1770
 San Francisco, CA 97143
 Phone: 415-502-3598
 Email: Pmunster@medicine.ucsf.edu

Date: September 25, 2017

To: Experimental Therapeutics and Rare Tumor Committee

From: Gary Schwartz, MD
 Pamela Munster, MD

Re: **Experimental Therapeutics and Rare Tumor Committee Meeting**

Date: **Saturday, November 4, 2017**

Time: **8:00am – 11:30am Central**

Location: Loews Chicago O’Hare - Rosemont, IL 60018
 Avedon D

Call-In Information: (800) 501-8979 / Access Code: 8087368

AGENDA

1. NCI – Quality Imaging Network Presentation
Amita Shukla-Dave, Ph. D.
 Deputy Service Chief Predictive Informatics
 Director Quantitative Imaging
 Associate Attending Physicist
 Departments of Medical Physics and Radiology
 Memorial Sloan-Kettering Cancer Center

2. Status update on activated current trials: *Munster*

a.	A091101 (suspended)	Carboplatin-paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) – A Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	E. Vokes
b.	A091202	A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in	M. Pishvaian

		Patients with Previously Treated, Unresectable Myxoid Liposarcoma	
c.	A091302	Randomized Phase II study of Sorafenib With or Without Everolimus in Patients with Radioactive Iodine Refractory Hürthle Cell Thyroid Cancer	E. Sherman
d.	A091304(suspended)	A Phase I/Randomized Phase II Study of MLN-0128 vs. Pazopanib in Patients with Advanced/Unresectable and/or Metastatic Sarcoma	W. Tap
e.	A091305	A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, in Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer	R. Smallridge
f.	A091401 (suspended to pre-registration)	Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	S. D'Angelo
g.	A091404	A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers	A. Ho

3. Status update on current trials in development: *Schwartz*

a.	A091603	A Randomized Trial of Adjuvant Nivolumab or Expectant Observation following Neoadjuvant Ipilimumab plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or recurrent Mucosal Melanoma.	A. Shoushtari R. Carvajal
b.	A091605	Randomized Phase II Study of Stereotactic Body Radiotherapy + anti-PD1 antibody (pembrolizumab) in advanced Merkel Cell Carcinoma	J. Luke S. Chmura
c.	A091607	A randomized phase II study of CDX-1401 in combination with Atezolizumab in patients with locally advanced or metastatic NY-ESO-1 positive synovial sarcoma	S. Robinson

4. Status of Concepts: *Munster*

a.		Phase II Randomized Study of Atezolizumab (PDL-1 inhibitor) alone or in combination with Obinutuzumab (anti-CD20) for Recurrent-Metastatic HPV positive tumors, following progression of disease on previous lines of therapy (A091704)	M. Matsangou
b.		An Open-Label Phase II Study with Safety Lead-In of MLN0128 in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Ewing sarcoma, and Osteosarcoma (A091703)	E. Slotkin